# Lirum Therapeutics, Inc. — Form D

Lirum Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2023-02-23. The offering totals $10.0M, of which $6.3M was reported sold. Industry: Biotechnology.

## Offering

- Filed: 2023-02-23
- Form: D
- Accession: 0001104659-23-024550
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $10.0M
- Amount sold: $6.3M
- Remaining: $3.7M
- Minimum investment: $5K
- Investors: 53
- Date of first sale: 2023-02-08
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-474079

## Issuer

- Name: Lirum Therapeutics, Inc.
- CIK: 0001965411
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 590 MADISON AVENUE, NEW YORK, NY, 10022
- Phone: 917-376-2350

## Officers, directors & promoters (5)

| Name | Role | Location |
| --- | --- | --- |
| Ivan Bergstein | Director | New York, NY |
| Kenneth Hoberman | Director | New York, NY |
| Daniel Hume | Director | LOVELAND, OH |
| Mark Sard | Director | New York, NY |
| Kenneth Hoberman | Executive Officer | New York, NY |

## More

- [CIK 1965411 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1965411&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001104659-23-024550.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.